Mitotic entry, a critical decision point for maintaining genetic stability, is governed by the cyclin B/Cyclin dependent kinase 1 (Cdc2) complex. In Xenopus oocytes and early embryos, accumulation of cyclin B activates Cdk1, which then phosphorylates and activates the positive regulator Cdc25 in an autocatalytic feedback loop. However, cyclin B levels do not increase as some human cells approach mitosis, and the key factors regulating Cdk1 activation in human cells are unknown. We report here that reducing cyclin A expression by RNA interference (RNAi) in primary human fibroblasts inhibited activation of Cdc25B and Cdc25C and dephosphorylation of Cdk1 on tyrosine (tyr) 15. These results were reproduced in U2-OS cells by inducing the expression of a dominant-negative (dn) mutant of Cdk2, the principal cyclin A binding partner. Cdk2-dn induction could inhibit Cdc25B activity and foster Cdk1 tyr phosphorylation within the S phase, temporally dissociating these events from Cdk1 activation at mitosis. In contrast, reducing Cdk1 expression delayed mitotic entry without markedly impairing Cdc25B or Cdc25C activity. These results suggest that cyclin A/Cdk2 complexes are key regulators of Cdc25 and Cdk1 activation in human cells. This pathway appears to be commonly deregulated in cancer.
Introduction
Entry into mitosis is perhaps the most critical juncture for maintaining genetic integrity in eukaryotic cells. An error in segregation of sister chromatids during mitosis or transmission of a new mutation may result in the death of one or both daughter cells. For long-lived metazoans, another deleterious outcome can be the development of a fatal malignancy. The cyclin B/Cdk1 complex is essential for entry into mitosis (Riabowol et al., 1989; Norbury and Nurse, 1990; Maller, 1991) . To forestall premature mitosis, this complex is inactivated by phosphorylation of Cdk1 on tyrosine (tyr) 15 and threonine 14 residues by kinases such as Wee1 and Myt1 (Kumagai and Dunphy, 1992; Hoffmann et al., 1993; Mueller et al., 1995; Parker et al., 1995) . The activation of the Cdk1 complex requires dephosphorylation of these residues by phosphatases of the Cdc25 family (Izumi et al., 1992; Kumagai and Dunphy, 1992; Hoffmann et al., 1993) . Cdc25B and Cdc25C have been implicated in this event in mammalian cells (Strausfeld et al., 1994; Lammer et al., 1998; Bulavin et al., 2002) .
A key concept in mitotic regulation is that Cdk1 activation is subject to a positive feedback loop (Novak and Tyson, 1993) . Active Cdk1 complexes isolated from mammalian cells and Xenopus oocytes can activate Cdc25 in vitro (Hoffmann et al., 1993) . However, sufficient amounts of active Cdk1 complex and/or positive regulators such as Cdc25 must be generated to exceed a critical threshold and initiate the positive feedback loop. Accumulation of cyclin B appears to serve as a trigger for the process in the Xenopus systems. In contrast, cyclin B is not strongly induced as some human cells approach mitosis (Hu et al., 2001) , and the trigger(s) for Cdk1 activation in such cells has remained unknown. Candidate regulators of Cdk1 activation include Plx1, the Xenopus homolog of human Plk1 (Krek et al., 1993; Kumagai and Dunphy, 1996; Nigg, 1998; Qian et al., 1998) and Cdc25B. In mammalian somatic cells, the contribution of Plk1 to initiation of mitosis is not clear (Mundt et al., 1997; Liu and Erikson, 2002) . Immunodepletion of Cdc25B from hamster BHK21 cell extracts, microinjection of an anti-Cdc25B antibody in Hs68 cells (Nishijima et al., 1997; Lammer et al., 1998) , and overexpression of a dominant-negative (dn) Cdc25B mutant in HeLa cells cause G2/M arrest (Gabrielli et al., 1996) . However, both Cdc25B and Plk1 require phosphorylation for full activation and the responsible kinase(s) is undetermined (Baldin et al., 1997; Gabrielli et al., 1997; Lammer et al., 1998; Ellinger-Ziegelbauer et al., 2000; Theis-Febvre et al., 2003) .
In this study, we investigated the role of cyclin A/Cdk2 complexes in the initiation of mitosis in human cells. The abundance and activity of these complexes rises strongly during S and G2 phases, suggesting that they are well positioned to influence preparations for mitosis. Although most studies of Cdk2 have focused on its role in DNA synthesis (Fang and Newport, 1991; Tsai et al., 1991; van den Heuvel and Harlow, 1993) , we and others have reported an additional function of Cdk2 in regulating mitotic entry and Cdk1 tyrosine dephosphorylation (Guadagno and Newport, 1996; Hu et al., 2001) . We present evidence here that cyclin A/Cdk2 complexes are major regulators of Cdc25B activation within the S phase and Cdc25C activity at G2/M, thereby antagonizing Cdk1 tyrosine phosphorylation. Deregulation of cyclin A/Cdk2 complexes and Cdc25B is common in cancer (see discussion). Our studies provide evidence that these proteins are linked through a common pathway that contributes to mitotic initiation.
Results
Cyclin A complexes are required for efficient progression of primary human cells through S and G2 phases To inhibit Cdk2 function within S and G2 phase human diploid fibroblasts (hdfs), we targeted the expression of cyclin A. Cyclin A is the major activating subunit of Cdk2 during these phases and must be newly synthesized in each cell cycle, making it an attractive candidate for RNA interference (RNAi). Cyclin A RNAi primarily delayed the progression of synchronized hdfs through the G2 phase ( Figure 1a ). Higher concentrations of siRNA led to additional modest S phase delays (data not shown). These results are consistent with our previous observation following induction of a dominant-negative mutant (Cdk2-dn) in U2-OS cells (Hu et al., 2001 ) that G2 is the phase most sensitive to Cdk2 inhibition. A G2 delay was also observed following cyclin A RNAi in HeLa cells (data not shown). RNAi reduced cyclin A protein levels in hdfs by more than 80% after 48 h without nonspecific reduction in other protein levels (Figure 1b ). The total Cdk2 activity was also inhibited by more than 80%, whereas cyclin E-associated kinase activity was not affected (Figure 1c ). The activation of S phase checkpoint proteins such as Chk1 was not observed (data not shown).
Cyclin A complexes antagonize Cdk1 tyr-15 phosphorylation
Cyclin B and Cdk1 levels were unaffected in the cyclin A RNAi sample (Figure 2a ). Despite the higher fraction of cells with a 4N DNA content, cyclin B/Cdk1 kinase activity was reduced by ca. 60% (Figure 2b ). Immunoblotting of cyclin B complexes with a phosphospecific antibody demonstrated that the Cdk1 inhibition was accompanied by markedly increased tyr-15 phosphorylation (Figure 2c) . In preliminary experiments, increased Cdk1 tyr-15 phosphorylation was also observed following cyclin A RNAi in HeLa cells (data not shown). We then asked whether the activity of Cdc25 phosphatases was reduced by cyclin A RNAi in hdfs, by immunoprecipitating these phosphatases and assaying their ability to activate cyclin B/Cdk1 complexes in vitro. Both Cdc25C and Cdc25B activities were reproducibly inhibited in the cyclin A RNAi samples (Table 1) . In contrast, Cdc25A activity was not inhibited by cyclin A RNAi (unpublished data). Cyclin A/Cdk2 complexes regulate Cdc25B and Cdc25C activity
To assess further the generality and timing of cyclin A-Cdk2's effects on Cdk1 activation, we sought to inhibit this complex in U2-OS cells. The shorter cell cycle time and more uniform growth properties of U2-OS cells allow superior synchronization compared to hdfs. Cyclin A RNAi did not strongly reduce cyclin A levels in these cells. However, immunodepletion experiments confirmed that Cdk2 is the major if not exclusive binding partner for cyclin A in U2-OS cells (Figure 3a) . We therefore inhibited cyclin A/Cdk2 function using a U2-OS cell clone generated in our laboratory that permits rapid induction of Cdk2-dn (dn.4; Hu et al., 2001) . The Cdk2-dn has a single amino-acid substitution at position 145 (Asp-Asn) that interferes with phosphotransfer between ATP and substrates (De Bondt et al., 1993) . Our prior studies with Cdk2-dn induction in dn.4 showed a G2 delay, associated with Cdk1 tyr-15 phosphorylation (Hu et al., 2001 ). The delay is distinct from activation of DNA replication and damage checkpoint pathways in that it is not abrogated by treatment with the potent checkpoint antagonist caffeine (Hu et al., 2001) . Furthermore, the G2 delay is devoid of markers of checkpoint activation such as increased p53 and Gadd45 (J Mitra, unpublished observation) or Chk1 activation (S Maude and GH Enders, unpublished observation). Based on the positive feedback model, the higher Cdk1 tyr-15 phosphorylation of G2/M cells with cyclin A/Cdk2 inhibition might be a secondary consequence of arresting cells in G2, rather than a primary effect of cyclin A/Cdk2 inhibition. Using synchronized cells, we asked whether Cdk1 tyr-15 phosphorylation mediated by Cdk2 inhibition could be temporally dissociated from G2 arrest and blockade of the major Cdk1 activation that occurs at mitosis. Cells were synchronized in the S phase with hydroxyurea (HU) and released, with or without Cdk2-dn induction. Consistent with other studies, increased Cdk1 activity was observed ca. 12 h after release from the HU block, as the lead fraction of cells reached G2/M (Figure 3b, panel 3 ). This activation was inhibited by ca. 75% upon induction of Cdk2-dn. However, Cdk1 tyr-15 phosphorylation occurred as early as 6 h into the S phase upon Cdk2-dn induction ( Figure 3B , panel 1), indicating this effect to be a direct consequence of inhibition of Cdk2 function, independent of G2 arrest and blockade of the mitotic activation of Cdk1. Coincident with the timing of Cdk1 phosphorylation, the induction of Cdk2-dn reduced the specific activity of Cdc25B early in the S phase (Figure 3b, panel 4) . As previously described (Hoffmann et al., 1993) , the activity of Cdc25C was induced during G2/M transition (Figure 3b, panel 6 ). Cdc25C activation was also strongly inhibited by Cdk2-dn, accompanied by a modest reduction in Cdc25C protein level (Figure 3b (Lammer et al., 1998) . The restriction of Cdc25C activation to G2/ M suggests that either a threshold level of cyclin A/Cdk2 activity must be achieved and/or other events must also occur to allow Cdc25C activation. We considered the possibility that the observed effects on Cdc25B and C activation were secondary to the inhibition of cyclin A/Cdk1 complexes, because cyclin A has been shown to associate with Cdk1 in Xenopus extracts (Guadagno and Newport, 1996) . Immunodepletion of Cdk2 from extracts of the late S phase/G2/M synchronized cells reduced cyclin A levels by 80% without much change in Cdk1 levels (Figure 3a) . Immunoprecipitation of the remaining cyclin A from the immunodepleted extract failed to yield detectable amounts of Cdk1 (Figure 3a) , indicating that Cdk1-cyclin A complexes constituted at most a small fraction of cyclin A complexes.
Specific inhibition of Cdk1 activity does not markedly impair Cdc25B and Cdc25C activities
Our time-course experiments in Figure 3 argued that Cdk1 tyr-15 phosphorylation observed with Cdk2 inhibition was not a consequence of blockade of Cdk1 activation at mitosis. To further exclude this model, we specifically inhibited Cdk1 activity using RNAi and assayed the effect on Cdc25 phosphatases. In cells released from a HU block, Cdk1 RNAi mediated a G2/M delay (Figure 4a ). Cdk1 levels and cyclin Bassociated kinase activity were strongly reduced, whereas levels of proteins not targeted remained unchanged (Figures 4b and c) . Cdc25B and Cdc25C phosphatase activities were assayed 16 h after release from HU, as the lead peak of cells reached G2/M (Figure 4b) . No difference in Cdc25B and Cdc25C phosphatase activity was observed between Cdk1 depleted and control samples (Figure 4c ). These results suggest that the positive feedback loop between Cdk1 and the phosphatases, if operative in these cells, is not the dominant activator of the phosphatases during interphase (Figure 4c ).
Discussion
The key molecular events that activate Cdk1 and initiate mitotic entry have remained undetermined in human cells. The accumulation of cyclin B contributes to Cdk1 activation in the Xenopus experimental systems, but cyclin B was not induced as U2-OS cells approached and Cdc25C activity. This linkage tethers preparations for mitosis to conditions favorable for S phase progression. In the setting of DNA damage, Cdk2 becomes inhibited by phosphorylation on tyr 15, induction of the potent Cdk2 inhibitor p21WAF1/Cip1, and degradation of cyclin D (Poon et al., 1996; Poon et al., 1997; Agami and Bernards, 2000; Goldstone et al., 2001; Falck et al., 2002) . The latter effect mediates redistribution of p21 and the related Cdk inhibitor p27 from Cdk4 and Cdk6 complexes to Cdk2 complexes (Agami and Bernards, 2000) . These responses have been viewed as mechanisms to inhibit DNA synthesis, but our results imply that they also promote phosphorylation of Cdk1 on tyr 15 and inhibit mitotic entry. Recently, RNAi directed against Cdk2 in several human cancer cell lines and deletion of the Cdk2 gene in mouse cells has been shown to impose surprisingly little cell cycle delay (Berthet et al., 2003; Ortega et al., 2003; Tetsu and McCormick, 2003) . These observations contrast with those described here and a vast body of literature in which inhibition of Cdk2 complexes via each of the following methods strongly inhibited cell cycle progression: (1) microinjection of antibodies directed against Cdk2 and its cyclin partners, (2) expression of a Cdk2-dn mutant, (3) endogenous and exogenous expression of specific Cdk inhibitor proteins, (4) immunodepletion of Cdk2 complexes in Xenopus extracts, (5) mutation of Cdk2 cyclin partners in mice and Drosophila, and (6) treatment of cells with small molecule Cdk inhibitors. Thus, it is evident that the selective absence of Cdk2 is less deleterious for cell cycle progression than the loss of cyclin/Cdk2 complexes or the presence of inhibited Cdk2 complexes. We offer two models that are not mutually exclusive to reconcile these disparities. In the first model, the absence of Cdk2 allows another Cdk(s) to bind to Cdk2 cyclin partners, compensating for Cdk2 loss. Consistent with this notion, substantial cyclin A-associated kinase activity was found in the Cdk2-'knockout' cells (Berthet et al., 2003; Ortega et al., 2003) . This model is also consistent with the numerous instances in which closely related members of a cell cycle regulatory protein family have displayed compensatory function in the absence of one family member (cf. Wu et al., 2001) . In the second model, Cdk2 complexes act primarily as negative regulators that inhibit cell cycle progression when inactive, rather than as essential activators. For example, inactive Cdk2 complexes could block access of other Cdks to critical sites of function. Substantial further experimentation will be required to evaluate these models.
Deregulation of Cdk2 as well as Cdc25B phosphatase activities (Galaktionov et al., 1995; Malumbres and Barbacid, 2001 ) are common events in cancer and associated with poor prognosis. Our studies provide evidence that these proteins are linked through a common pathway that contributes to initiation of mitosis. Perturbation of this pathway may override mitotic delays in response to DNA damage and generate genetic instability. 
Materials and methods

Cell culture and synchronization
Early passage (passages 5-8) normal hdfs obtained from foreskin (a kind gift from Dr Hung Tseng, University of Pennsylvania) were cultured in DMEM medium containing 10% fetal calf serum (FCS), penicillin, and streptomycin (PS). For HU block and release experiments, U2-OS cells were cultured in 1 mM HU for 24 h, washed in phosphate-buffered saline (PBS), released into fresh medium, and harvested at the indicated time points. Hdfs were synchronized by serum deprivation (0.2% FCS for 48 h). Stimulation was carried out with 10% FCS.
Flow cytometry, preparation of extracts, kinase assays, immunoprecipitation, immunodepletion, and immunoblotting These methods were performed as described previously (Hu et al., 2001) . Immunodepletion of Cdk2 was achieved using two successive aliquots of 12 mg of antibody (M2, Santa Cruz).
Cdc25B and Cdc25C phosphatase assays
Inactive cyclin B/Cdk1 complexes were immunoprecipitated from HU-arrested U2-OS cells using protein G beads and a mouse monoclonal antibody directed against cyclin B (GNS1, Santa Cruz). The complexes were eluted from the beads with 20 mM glycine, pH 3, and neutralized. Cdc25B and Cdc25C were immunoprecipitated on protein A beads from freshly prepared cell extracts with rabbit antibodies (C20 and H85, respectively; Santa Cruz). The phosphatases were incubated with cyclin B/Cdk1 complexes for 1 h at 301C in 100 ml of phosphatase assay buffer (20 mM Tris-Cl, pH 8.3, 150 mM NaCl, 2 mM EDTA, 0.01% Triton X-100, and 5 mM DTT). The activation of cyclin B/Cdk1 complexes was assayed by incorporation of 32 P from g-labeled ATP into histone H1 (Hu et al., 2001) . Polyacrylamide gels were scanned and quantitated using Phosphorimager Storm 840 (Amersham Biosciences) and software IQ Mac V1.2.
RNAi and transfection
21-nucleotide siRNA duplexes (Dharmacon Research, Lafayette, CO) were transfected into cells during the later half of the cell synchronization period. In all, 14-48 ml of Oligofectamine (Life Technologies) and 30-100 ml (20 mM stock solution) of siRNA duplex were used per 6 cm culture plate in a total volume of 1.5-3 ml of media. The following target sequences were used for siRNAs: cyclin A, 5 0 -AACTACATTGA-TAGGTTCCTG -3 0 ; Cdk1, 5 0 -AAGGGGTTCCTAG-TACTGCAA-3 0 . A two base pair mismatch of the cyclin A target sequence was used as control.
